BRCA Carriers Benefit From Ovarian Cancer Risk-Reducing Surgery

Healthy women who carry BRCA gene mutations should not be discouraged from undergoing risk-reducing bilateral salpingo-oophorectomy (BSO) due to older age, according to investigators of a study focused on BRCA carriers. The study examined the outcomes for women with BRCA1 and BRCA2 mutations, which significantly increase the lifetime risk of developing ovarian and breast cancers. Bilateral salpingo-oophorectomy involves the surgical removal of both fallopian tubes and ovaries, a procedure known to drastically reduce the risk of ovarian cancer, a disease often diagnosed at late stages with poor prognoses. For BRCA1 carriers, the lifetime risk of ovarian cancer can be as high as 44%, and for BRCA2 carriers, it can be up to 17%. Similarly, the lifetime risk of breast cancer for BRCA1 carriers is between 55% and 72%, and for BRCA2 carriers, it ranges from 45% to 69%.

The research aimed to assess the benefits and potential drawbacks of BSO in a cohort of women with these genetic predispositions. While the primary benefit is the substantial reduction in ovarian cancer risk, the surgery also impacts breast cancer risk, particularly for postmenopausal women. The study's findings suggest that the protective effect of BSO against ovarian cancer is significant across different age groups, provided the individuals are otherwise healthy. This implies that age alone should not be a barrier to considering this preventative measure, especially given the high incidence and mortality rates associated with ovarian cancers in the general population and even more so in BRCA mutation carriers.

Previous research has established the efficacy of BSO in reducing ovarian cancer incidence and mortality among BRCA mutation carriers. However, discussions around the optimal timing and the influence of age on surgical outcomes and benefits have persisted. This latest study contributes to the body of evidence by reinforcing the message that proactive surgical intervention remains a crucial strategy for managing cancer risk in this specific population. The decision to undergo BSO is complex, involving considerations of surgical risks, potential menopausal side effects, and the psychological impact of the procedure, alongside the significant reduction in cancer risk. The study's conclusion underscores the importance of personalized risk assessment and counseling for BRCA carriers, ensuring they are fully informed about all available options for cancer prevention.

Ovarian cancer is the eighth most common cancer among women globally, and it is the eighth deadliest. The American Cancer Society estimates that in 2024, approximately 21,980 women will be diagnosed with ovarian cancer, and about 13,850 will die from it. The high mortality rate is largely due to the lack of early detection methods and the tendency for the disease to spread before symptoms become apparent. Genetic mutations, such as those in the BRCA1 and BRCA2 genes, are responsible for about 5% to 10% of all ovarian cancers, highlighting the critical role of genetic testing and preventative strategies for at-risk individuals. The findings from this study provide further support for the established guidelines recommending BSO for BRCA carriers, emphasizing its continued relevance and benefit regardless of a patient's age, as long as they are in good health.